EMEA-001214-PIP06-20
Key facts
| Invented name |
Fasenra
|
| Active substance |
Benralizumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0314/2020
|
| PIP number |
EMEA-001214-PIP06-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of bullous pemphigoid
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|